BACK (IMAC Holdings) Cash Flow from Financing: $4.75 Mil (TTM As of Sep. 2025)


What is IMAC Holdings Cash Flow from Financing?

IMAC Holdings BACK Cash Flow from Financing is $4.75 Mil as of Sep. 2025. The stock has 7 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2025, IMAC Holdings paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $1.44 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, IMAC Holdings earned $1.44 Mil on financial activities for the three months ended in Sep. 2025.


IMAC Holdings  (OTCPK:BACK) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

IMAC Holdings's issuance of stock for the three months ended in Sep. 2025 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

IMAC Holdings's repurchase of stock for the three months ended in Sep. 2025 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

IMAC Holdings's net issuance of debt for the three months ended in Sep. 2025 was $1.44 Mil. IMAC Holdings received $1.44 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

IMAC Holdings's net issuance of preferred for the three months ended in Sep. 2025 was $0.00 Mil. IMAC Holdings paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

IMAC Holdings's cash flow for dividends for the three months ended in Sep. 2025 was $0.00 Mil. IMAC Holdings received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

IMAC Holdings's other financing for the three months ended in Sep. 2025 was $0.00 Mil. IMAC Holdings received $0.00 Mil on other financial activities.


IMAC Holdings Cash Flow from Financing Related Terms


IMAC Holdings Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for IMAC Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMAC Holdings Cash Flow from Financing Chart

IMAC Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 8.81 14.54 4.20 4.02 3.82

IMAC Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 1.45 0.56 1.31 1.44

IMAC Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

IMAC Holdings's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

IMAC Holdings's Cash from Financing for the quarter that ended in Sep. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of $4.75 Mil mean?
IMAC Holdings (BACK) has a Cash Flow from Financing of $4.75 Mil as of Sep. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for IMAC Holdings and its competitors.
Is IMAC Holdings' Cash Flow from Financing too high?
IMAC Holdings' current Cash Flow from Financing is $4.75 Mil.
How does IMAC Holdings' Cash Flow from Financing compare to FCHS and NHLG?
IMAC Holdings' Cash Flow from Financing of $4.75 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for IMAC Holdings and its competitors. IMAC Holdings's current Cash Flow from Financing is $4.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current Cash Flow from Financing of $4.75 Mil. The current Cash Flow from Financing is $4.75 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For IMAC Holdings (BACK), the current Cash Flow from Financing is $4.75 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.